Cardiologia Croatica, Vol. 6 No. 1-2, 2011.
Pregledni rad
Ranolazine: a new possibility and a new mechanism in the treatment of chronic angina pectoris.
Goran Krstačić
orcid.org/0000-0003-0427-7229
; Poliklinika za prevenciju kardiovaskularnih bolesti i rehabilitaciju, Zagreb, Hrvatska
Sažetak
In treatment of chronic angina pectoris in the
last few years, besides the medicines with antianginal effect
(adrenergic receptor beta blockers, calcium antagonists and
nitrates) even ranolazine may be applied. This innovative drug
having effect on pathological process that occurs at a very early stage of ischemia, may block harmful effects that occur in
cascade process. Ranolazine is the first antianginal metabolic
modulator that has appeared in the last 25 years of treatment
of angina pectoris, having inhibition effect on sarkoplasmatic
late Na channels with no significant effect on heart rate and
blood pressure as well as respiratory tract. Apart from proved
antianginal effect, ranolazine represents a new possibility of
treatment of heart diseases associated with impaired homeostasis of myocardial ions, especially in patients with impaired
homeostasis of Na ions as it occurs in heart failure. The inhibition of late Na channels may be a new antiarrhythmic approach to supraventricular and ventricular arrhythmias (tachycardias), while potential studies of heart failure with systolic
and/or diastolic dysfunction and atrial fibrillation represent the
future of research of potential benefit of application of ranolazine.
Ključne riječi
angina pectoris; ranolazine; arrhythmia; heart failure
Hrčak ID:
71487
URI
Datum izdavanja:
7.2.2011.
Posjeta: 4.107 *